Business Context and Reporting Period
This Form 8-K is a current report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc., despite the metadata request) on January 9, 2025. The filing announces a corporate action taken by the Board of Directors regarding a reverse stock split in connection with a proposed merger with Kalaris Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a capital structure change.
Material Changes
- Reverse Stock Split: The Board approved a one-for-twenty-three (1-for-23) reverse stock split of AlloVir's common stock.
- Effective Date: The split will take effect at 4:05 p.m. Eastern Time on January 15, 2025.
- Trading Resumption: Common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market on January 16, 2025.
- Shareholder Treatment: No fractional shares will be issued; shareholders entitled to fractions will receive cash payments based on the closing price on January 15, 2025.
- Identification: A new CUSIP number (019818202) will be assigned upon effectiveness.
Guidance, Outlook, and Risks
Management Commentary: The reverse split ratio falls within the range previously authorized by stockholders at a Special Meeting held on January 9, 2025. The action is part of the proposed merger process with Kalaris Therapeutics, Inc.
Risks and Contingencies: The filing explicitly states it is not an offer to buy or sell securities. Investors are urged to read the Form S-4 and Proxy Statements for complete information regarding the merger and reverse split before making voting decisions.
Investor Verification Checklist
- Verify the 1-for-23 reverse split ratio and its impact on share count and price.
- Confirm the January 15, 2025 effective time and January 16, 2025 trading resumption date.
- Review the Form S-4 and Proxy Statements filed with the SEC for details on the proposed merger with Kalaris Therapeutics, Inc.
- Check the new CUSIP number (019818202) for trading purposes post-split.
- Understand the cash-in-lieu-of-fractional-shares policy based on the January 15 closing price.